The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2022 | Risk model to predict delivery of adjuvant chemotherapy
Alessandro Brunelli, MD, St. James’s University Hospital, Leeds, UK, discusses a risk model to predict the delivery of adjuvant chemotherapy which was evaluated in a multi-center retrospective analysis. This study identified several factors associated with the probability of initiating adjuvant chemotherapy after lung resection in node-positive patients, which can be used to support decision-making on the timing of systemic treatment. This interview took place during the virtual European Lung Cancer Congress 2022.
